We're looking for people to collaborate and work on these... If interested get in touch with us.

MCARD

Developing and validating minimally invasive biomarkers for aging. A community research project to create targets for the biology of aging and dramatically reduce timelines for Clinical Trials.

Aging Clocks Assessment Program

Can aging clocks accelerate discoveries in aging biology by serving as precise biomarkers for lifespan and health outcomes? We propose a Clocks Assessment Program (CAP) to validate the predictive power of methylation clocks as tools, helping streamline research and fast-track the development of therapies for age-related diseases.

How can we leverage innovations in clinical trials such as centralized infrastructure, platform trials and risk-based monitoring to improve efficiency? Proposals to streamline drug development for age-related diseases and aging drugs.

Impactful Experiment - Prospective Study for Predictive Lifespan

Run the first definitive test on whether any current aging clocks can predict lifespan.

Disease-Animal Model Map

A disease-animal model map can help researchers identify the most suitable animal models for their target diseases, and result in optimized experimental accuracy, reduced costs, and accelerating target therapy research.

These are questions we believe need answers, reach out to us if you are working on these.

Are there drugs associated with extension of latest child birth based on medical records?

Identifying drugs that extend childbearing age could reveal targets for reproductive longevity, offering clues for aging interventions and improving quality of life in advanced age.

"Obesity is a risk factor for a lot of diseases; Aging is much worse" - Are there appropriate statistics for this statement? e.g. What is the hazard ratio of obesity across 5-15 diseases, and then ten years of age for 5-15 diseases?

Comparing obesity and aging allows us to quantify their impact on disease risk via multiple diseases' hazard ratios. This can help us priortize interventions targeting aging as a broader more influential health determinant.

What are Effect Sizes for Rapamycin Trials?

One of the many obstacles to run Rapamycin Trial is a need for better effect size estimates. We believe the steps to estimate the effect size are to:

• Define the mTOR/Rapamycin pathway: Investigate similar pathways
• Collect animal study results on drugs on those similar pathways
• Collect clinical trial results on drugs on those similar pathways
• Collect Rapamycin animal study results and extrapolate data

Introduction to the Biology and Landscape of Geroscience

A video primer presentation by Martin Borch Jensen built for people new to the field of aging biology. During this presentation Martin defines aging and its associated problems, the various biological mechanisms of aging, and current challenges plaguing the field.

‘Aging Curriculum’ Journal Club

The journal club goes through landmark discoveries and topics in aging biology, with a focus on primary research papers. It’s intended for people who have gained familiarity with topics within aging biology and want to refine their understanding of what’s possible and what’s next. Content includes link to papers, slides from presenters, and notes from our discussions. Chronologically going through these topics highlight how young the field is (a couple of decades), and how even major conference topics often arose from a single bold experiment. We read between the lines to evaluate strong claims, deduce limitations, and discuss implications.

Contributions from Divya Cohen, Tara Mei, Madison Ueland, Kush Sharma, Lada Nuzhna, Martin Borch Jensen.

Age-Related Disease Overview

Created through our Apprenticeship Program, this overview includes data on incidence, etiology, clinical trials, animal models, and more. Designed to reduce duplications of efforts from longevity biotechnology companies while choosing disease(s) to test drug candidate efficacy.